In late July, Vanderbilt University Medical Center will begin recruiting up to 1,000 volunteers in a late-stage study of an experimental COVID-19 vaccine developed by Moderna Inc. in collaboration with the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.

An experimental coronavirus vaccine stimulated robust immune responses against SARS-CoV-2, the virus that causes COVID-19, and raised no serious safety concerns in an early-stage clinical trial.

This week researchers at Vanderbilt University Medical Center (VUMC), the University of North Carolina at Chapel Hill and Gilead Sciences reported that remdesivir potently inhibited SARS-CoV-2, the virus which causes COVID-19, in human lung cell cultures and that it improved lung function in mice infected with the virus.

Vanderbilt University Medical Center investigators are leading a new study that examines the transmission of SARS-CoV-2, the virus that causes COVID-19, within households in Nashville.

The investigational antiviral drug remdesivir can shorten the time to recovery in adults hospitalized with COVID-19, according to preliminary results of a clinical trial published last month in The New England Journal of Medicine.

Pediatricians at Monroe Carell Jr. Children’s Hospital at Vanderbilt are stressing the continued importance of well-child visit for infants, children and adolescents, particularly during the COVID-19 pandemic.

A comprehensive evaluation of the metabolic pathways that support Staphylococcus aureus (“staph”) growth during invasive bone infections could offer new targets for treatment.